What is a clinical trial?

A clinical trial is a research study involving human participants designed to evaluate medical interventions — such as drugs, devices, or behavioral strategies. Trials follow a structured protocol and are registered on ClinicalTrials.gov. They progress through phases: Phase 1 (safety), Phase 2 (efficacy), Phase 3 (large-scale comparison), and Phase 4 (post-market surveillance).

How do I find clinical trials I'm eligible for?

You can search ClinicalTrials.gov or use ClinicalMetric to filter by condition, phase, or location. Each trial listing includes eligibility criteria such as age range, sex, diagnosis, and prior treatment history. Contact the study team directly or ask your physician to refer you to a relevant trial.

Are clinical trials safe to participate in?

Clinical trials are conducted under strict ethical and regulatory oversight, including IRB approval and FDA regulation in the US. All participants must give informed consent after reviewing potential risks and benefits. Phase 1 trials carry more uncertainty, while Phase 3 trials involve interventions with an established safety profile. Participation is always voluntary and you may withdraw at any time.

What are the phases of clinical trials?

Clinical trials progress through four main phases. Phase 1 tests safety and dosing in a small group (20–80 people). Phase 2 evaluates efficacy and side effects in a larger group (100–300). Phase 3 compares the intervention against standard treatments in thousands of participants. Phase 4 occurs after approval and monitors long-term effects in the general population.

Do participants get paid for joining clinical trials?

Many clinical trials offer compensation for time and travel expenses, though payment structures vary widely by study. Compensation is not intended to be coercive. Some trials also cover treatment costs for participants. Always review the consent form carefully and ask the study coordinator about any financial considerations before enrolling.

Depression Clinical Trials 2026: Ketamine, Psilocybin, TMS & New Antidepressants

Medical Notice

This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.

Summary

Major depressive disorder affects over 280 million people worldwide. Despite decades of antidepressant development, approximately 30% of patients don't respond to standard treatments — classified as treatment-resistant depression (TRD). In 2026, depression research is experiencing a renaissance driven by psychedelic-assisted therapy, fast-acting NMDA receptor drugs, and precision psychiatry approaches. This guide covers what's being tested and how to participate.

Ketamine and Esketamine

Esketamine (Spravato), an intranasal ketamine derivative, is FDA-approved for treatment-resistant depression and major depressive disorder with suicidal ideation. It works within hours — unlike traditional antidepressants that take weeks. In 2026, trials are investigating:

Optimal dosing frequency and maintenance schedules for esketamine
IV racemic ketamine infusion protocols vs. intranasal esketamine
Combination with traditional antidepressants or psychotherapy
Biomarkers predicting ketamine response (EEG signatures, inflammatory markers)

Psilocybin-Assisted Therapy

Psilocybin (the active compound in "magic mushrooms") has shown remarkable efficacy in Phase 2 trials for treatment-resistant depression. The COMPASS Pathways Phase 3 trial (COMP360) is the largest psilocybin trial ever conducted, recruiting patients who have failed at least two antidepressants. Usona Institute is conducting parallel Phase 3 trials for MDD.

Psilocybin trials involve structured therapy sessions with trained therapists before, during, and after the drug experience. Participants typically receive 1–3 doses. Key exclusion criteria include personal or family history of psychosis or bipolar I disorder, current lithium use, and cardiovascular disease.

New Pharmacological Approaches

AMPA potentiators: Drugs that enhance glutamate signaling via AMPA receptors (a downstream mediator of ketamine's effects) without dissociative side effects. Several are in Phase 2.

Zuranolone (Zurzuvae): FDA-approved in 2023 — a neuroactive steroid GABA-A receptor modulator taken as a 14-day oral course. Trials are exploring extended use and specific patient populations.

Anti-inflammatory approaches: A subset of depressed patients has elevated inflammatory markers (CRP, IL-6). Trials are testing anti-inflammatory drugs (including low-dose bupropion + naltrexone) specifically in this inflammatory-subtype population.

TMS and Brain Stimulation Trials

Transcranial magnetic stimulation (TMS) is FDA-approved for MDD and TRD. Accelerated TMS protocols (Stanford Neuromodulation Therapy — SNT) deliver multiple sessions per day over 5 days instead of the traditional 6-week course, showing rapid response in Phase 2. Deep TMS (dTMS) and theta burst stimulation (TBS) are also in active comparative trials.

Who Qualifies for Depression Trials

Most depression trials require a formal DSM-5 diagnosis of MDD confirmed by a structured interview, a minimum severity score (PHQ-9 ≥10, MADRS ≥20, or HDRS ≥17), and a specific treatment history. TRD trials typically require failure of 2–4 antidepressants at adequate dose and duration. Exclusion criteria commonly include active suicidal ideation with plan, psychotic features, bipolar disorder, and active substance use disorder.